Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Phase 3

Completed

Conditions: Thrombotic Thrombocytopenic Purpura

Interventions: Drug: Caplacizumab
Drug: Corticosteroids
Biological: anti-CD20 antibody

First Posted Date: 2022-07-21

Last Posted Date: 2025-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 56

Registration Number: NCT05468320

Locations: 🇮🇹
Investigational Site Number : 3800003, Avellino, Campania, Italy
🇮🇹
Investigational Site Number : 3800001, Milano, Lombardia, Italy
🇮🇹
Investigational Site Number : 3800006, Genova, Italy

and more 29 locations

A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: SAR441566
Drug: Placebo

First Posted Date: 2022-07-12

Last Posted Date: 2023-02-15

Lead Sponsor: Sanofi

Target Recruit Count: 38

Registration Number: NCT05453942

Locations: 🇩🇪
Investigational Site Number :2760001, Berlin, Germany

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Neoplasm

Interventions: Biological: SAR444200
Biological: Atezolizumab

First Posted Date: 2022-07-08

Last Posted Date: 2025-01-17

Lead Sponsor: Sanofi

Target Recruit Count: 33

Registration Number: NCT05450562

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center- Site Number : 8400004, Los Angeles, California, United States
🇺🇸
Icahn School of Medicine at Mount Sinai- Site Number : 8400005, New York, New York, United States
🇺🇸
Lifespan Corporation- Site Number : 8400002, Providence, Rhode Island, United States

and more 10 locations

A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan

Completed

Conditions: Atopic Dermatitis

First Posted Date: 2022-07-05

Last Posted Date: 2024-07-18

Lead Sponsor: Sanofi

Target Recruit Count: 80

Registration Number: NCT05442645

Locations: 🇨🇳
Investigational site-National Taiwan University Hospital, Taipei, Taiwan, China

Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Neoplasm

Interventions: Drug: Tusamitamab ravtansine

First Posted Date: 2022-06-23

Last Posted Date: 2025-04-06

Lead Sponsor: Sanofi

Target Recruit Count: 56

Registration Number: NCT05429762

Locations: 🇺🇸
Mary Crowley Cancer Research Center Site Number : 8400002, Dallas, Texas, United States
🇪🇸
Investigational Site Number : 7240002, Barcelona, Catalunya [Cataluña], Spain
🇹🇷
Investigational Site Number : 7920001, Ankara, Turkey

and more 4 locations

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Amlitelimab

First Posted Date: 2022-06-16

Last Posted Date: 2025-04-22

Lead Sponsor: Sanofi

Target Recruit Count: 446

Registration Number: NCT05421598

Locations: 🇨🇦
Investigational Site Number : 1240003, Quebec, Canada
🇨🇦
Investigational Site Number : 1240007, Trois-Rivieres, Quebec, Canada
🇺🇸
Treasure Valley Medical Research Site Number : 8400031, Boise, Idaho, United States

and more 110 locations

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine/Lixisenatide
Drug: IDegAsp
Drug: Metformin
Drug: SGLT2 inhibitor

First Posted Date: 2022-06-10

Last Posted Date: 2024-10-30

Lead Sponsor: Sanofi

Target Recruit Count: 582

Registration Number: NCT05413369

Locations: 🇨🇳
Investigational Site Number : 1560025, Harbin, China
🇨🇳
Investigational Site Number : 1560008, Baotou, China
🇨🇳
Investigational Site Number : 1560001, Beijing, China

and more 57 locations

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma Recurrent

Interventions: Drug: Isatuximab SC
Drug: Isatuximab IV
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Montelukast
Drug: Paracetamol / Acetaminophen
Drug: Diphenhydramine
Drug: Methylprednisolone

First Posted Date: 2022-06-06

Last Posted Date: 2024-11-14

Lead Sponsor: Sanofi

Target Recruit Count: 531

Registration Number: NCT05405166

Locations: 🇺🇸
Arizona Oncology Associates, PC - HAL- Site Number : 8400015, Prescott Valley, Arizona, United States
🇺🇸
Rocky Mountain Cancer Centers, LLP- Site Number : 8400021, Aurora, Colorado, United States
🇺🇸
Mayo Clinic- Site Number : 8400008, Jacksonville, Florida, United States

and more 143 locations